Immutep Ltd ADR (IMMP)

$0.38 0.00 (-0.44%)
Market Cap 56.86M
Revenue (ttm) 6.69M
Net Income (ttm) -39.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -594.62%
Debt to Equity Ratio 0.01
Volume 107,600
Avg Vol 418,292
Day's Range N/A - N/A
Shares Out 147.37M
Stochastic %K 41%
Beta 2.25
Analysts Sell
Price Target $1.50

Company Profile

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 8315 7003
Fax: 61 2 8569 1880
Address:
Australia Square, Level 32 264 George Street, Sydney, Australia
TheUsualSuspect007
TheUsualSuspect007 Aug. 10 at 10:56 AM
$IMMP
0 · Reply
theinvestaar
theinvestaar Aug. 10 at 3:04 AM
$IMMP
0 · Reply
ye81
ye81 Aug. 7 at 2:16 PM
$IMMP ⏳🚀🚀
1 · Reply
theinvestaar
theinvestaar Aug. 7 at 1:58 AM
$IMMP Come on Marc!??????
1 · Reply
FROSTCAT
FROSTCAT Aug. 6 at 11:53 AM
$IMMP Old projections don't matter the current setup and data are what count.
0 · Reply
rispi
rispi Aug. 6 at 9:28 AM
$IMMP Just a reminder to all the small ang pumpers around this ticker, they used to talk about 30 usd SP. And they do not even stop talking about finance!!!
0 · Reply
k3vl4r
k3vl4r Aug. 5 at 8:45 PM
$IMMP just hit 100% bullish probability on the 1h-1wk horizon, K3vl4r’s model is all in. One of their top AI reads, but I’ll let the chart speak. #stocks #trading
0 · Reply
FROSTCAT
FROSTCAT Aug. 5 at 2:00 PM
$IMMP let's go
0 · Reply
rispi
rispi Aug. 5 at 9:36 AM
$IMMP let's go fishing
0 · Reply
theinvestaar
theinvestaar Aug. 4 at 8:12 PM
$IMMP News tonight????
2 · Reply
Latest News on IMMP
Immutep granted new patent for eftilagimod alfa combination

2026-07-14T12:15:20.000Z - 27 days ago

Immutep granted new patent for eftilagimod alfa combination

IMMP

Immutep Post Mautre Overall Survival Data In First-Line NSCLC; Updates On TACTI-004 Analysis

2026-07-14T07:54:11.000Z - 27 days ago

Immutep Post Mautre Overall Survival Data In First-Line NSCLC; Updates On TACTI-004 Analysis

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

Jul 13, 2026, 8:00 AM EDT - 4 weeks ago

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

IMMP

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

Mon, 06 Jul 2026 14:31:00 -0400 - 5 weeks ago

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Mon, 06 Jul 2026 08:28:00 -0400 - 5 weeks ago

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

Thu, 02 Jul 2026 10:00:00 -0400 - 5 weeks ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

Wed, 01 Jul 2026 09:34:00 -0400 - 5 weeks ago

IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP

Tue, 30 Jun 2026 16:31:00 -0400 - 5 weeks ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP

Portnoy Law Firm Announces Class Action on Behalf of Immutep Limited Investors

Tue, 30 Jun 2026 09:36:00 -0400 - 5 weeks ago

Portnoy Law Firm Announces Class Action on Behalf of Immutep Limited Investors

Robbins LLP Urges IMMP Stockholders to Move for Lead Plaintiff Before the July 6, 2026 Deadline

Jun 29, 2026, 7:27 PM EDT - 6 weeks ago

Robbins LLP Urges IMMP Stockholders to Move for Lead Plaintiff Before the July 6, 2026 Deadline

IMMP

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immutep Limited (IMMP)

Wed, 24 Jun 2026 09:24:00 -0400 - 6 weeks ago

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immutep Limited (IMMP)

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

Wed, 17 Jun 2026 12:00:00 -0400 - 7 weeks ago

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

Immutep upgraded to Buy from Hold at Maxim

2026-06-17T12:06:14.000Z - 7 weeks ago

Immutep upgraded to Buy from Hold at Maxim

IMMP

IMMP Deadline Alert: Levi & Korsinsky Reminds Immutep Limited (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Wed, 10 Jun 2026 09:00:00 -0400 - 2 months ago

IMMP Deadline Alert: Levi & Korsinsky Reminds Immutep Limited (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

IMMP Investor Alert - Immutep Limited Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit

Tue, 09 Jun 2026 21:06:00 -0400 - 2 months ago

IMMP Investor Alert - Immutep Limited Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit

IMMP UPCOMING DEADLINE: Levi & Korsinsky Alerts Immutep Limited Stockholders of Securities Class Action - Contact the Firm

Mon, 08 Jun 2026 16:00:00 -0400 - 2 months ago

IMMP UPCOMING DEADLINE: Levi & Korsinsky Alerts Immutep Limited Stockholders of Securities Class Action - Contact the Firm

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Sun, 07 Jun 2026 14:16:00 -0400 - 2 months ago

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Sat, 06 Jun 2026 09:16:00 -0400 - 2 months ago

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Fri, 05 Jun 2026 14:50:00 -0400 - 2 months ago

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Robbins LLP Reminds IMMP Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Immutep Limited

Fri, 05 Jun 2026 13:57:00 -0400 - 2 months ago

Robbins LLP Reminds IMMP Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Immutep Limited

ROSEN, LEADING INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Fri, 05 Jun 2026 11:38:00 -0400 - 2 months ago

ROSEN, LEADING INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Thu, 04 Jun 2026 23:18:00 -0400 - 2 months ago

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors Should Contact SueWallSt

Thu, 04 Jun 2026 17:33:00 -0400 - 2 months ago

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors Should Contact SueWallSt

Immutep to present positive interim Phase I data for IMP761

2026-06-04T13:15:39.000Z - 2 months ago

Immutep to present positive interim Phase I data for IMP761

IMMP

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

Jun 4, 2026, 8:00 AM EDT - 2 months ago

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

IMMP

IMMP DEADLINE: Levi & Korsinsky Reminds Immutep Limited Investors of Upcoming Securities Class Action Deadline

Wed, 03 Jun 2026 09:00:00 -0400 - 2 months ago

IMMP DEADLINE: Levi & Korsinsky Reminds Immutep Limited Investors of Upcoming Securities Class Action Deadline

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Tue, 02 Jun 2026 23:13:00 -0400 - 2 months ago

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Tue, 02 Jun 2026 16:00:00 -0400 - 2 months ago

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

IMMP INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Tue, 02 Jun 2026 12:49:00 -0400 - 2 months ago

IMMP INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

Tue, 02 Jun 2026 09:00:00 -0400 - 2 months ago

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

ROSEN, A LONGSTANDING FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Mon, 01 Jun 2026 23:13:00 -0400 - 2 months ago

ROSEN, A LONGSTANDING FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 6, 2026 in Immutep Limited Lawsuit - IMMP

Mon, 01 Jun 2026 14:33:00 -0400 - 2 months ago

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 6, 2026 in Immutep Limited Lawsuit - IMMP

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Mon, 01 Jun 2026 11:52:00 -0400 - 2 months ago

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

IMMP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Sun, 31 May 2026 09:04:00 -0400 - 2 months ago

IMMP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

IMMP CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Sat, 30 May 2026 08:36:00 -0400 - 2 months ago

IMMP CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Sat, 30 May 2026 07:13:00 -0400 - 2 months ago

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 6, 2026 in Immutep Limited Lawsuit - IMMP

Fri, 29 May 2026 09:00:00 -0400 - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 6, 2026 in Immutep Limited Lawsuit - IMMP

IMMP UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Fri, 29 May 2026 08:19:00 -0400 - 2 months ago

IMMP UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

ROSEN, A LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Thu, 28 May 2026 14:45:00 -0400 - 2 months ago

ROSEN, A LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

SueWallSt Reminds Immutep Limited Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 6, 2026 - IMMP

Thu, 28 May 2026 09:00:00 -0400 - 2 months ago

SueWallSt Reminds Immutep Limited Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 6, 2026 - IMMP

ROSEN, A RANKED AND LEADING FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Wed, 27 May 2026 22:28:00 -0400 - 2 months ago

ROSEN, A RANKED AND LEADING FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMP Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Immutep Limited Securities Lawsuit - Contact Levi & Korsinsky

Wed, 27 May 2026 09:00:00 -0400 - 2 months ago

IMMP Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Immutep Limited Securities Lawsuit - Contact Levi & Korsinsky

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Tue, 26 May 2026 22:06:00 -0400 - 2 months ago

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMP Shareholder Alert: July 6, 2026 Lead Plaintiff Deadline in Immutep Limited Securities Class Action - Contact The Gross Law Firm

Tue, 26 May 2026 09:00:00 -0400 - 2 months ago

IMMP Shareholder Alert: July 6, 2026 Lead Plaintiff Deadline in Immutep Limited Securities Class Action - Contact The Gross Law Firm

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

Tue, 26 May 2026 09:00:00 -0400 - 2 months ago

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Mon, 25 May 2026 22:06:00 -0400 - 2 months ago

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMP SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Mon, 25 May 2026 09:30:00 -0400 - 2 months ago

IMMP SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Sun, 24 May 2026 22:45:00 -0400 - 2 months ago

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Thu, 21 May 2026 17:34:00 -0400 - 2 months ago

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

IMMP EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Thu, 21 May 2026 10:18:00 -0400 - 2 months ago

IMMP EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

IMMUTEP LIMITED (IMMP) INVESTOR ALERT Investors With Large Losses in Immutep Limited Should Contact Bernstein Liebhard LLP To Discuss Their Rights

May 7, 2026, 9:03 AM EDT - 3 months ago

IMMUTEP LIMITED (IMMP) INVESTOR ALERT Investors With Large Losses in Immutep Limited Should Contact Bernstein Liebhard LLP To Discuss Their Rights

IMMP

Immutep receives noncompliance notification from Nasdaq

2026-04-30T14:06:28.000Z - 3 months ago

Immutep receives noncompliance notification from Nasdaq

IMMP

Immutep granted Orphan Drug Designation for eftilagimod alfa

2026-04-15T12:23:31.000Z - 4 months ago

Immutep granted Orphan Drug Designation for eftilagimod alfa

IMMP

Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

Apr 15, 2026, 8:00 AM EDT - 4 months ago

Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

IMMP

Immutep sees progress from Phase I study of LAG-3 agonist for autoimmune disease

2026-03-19T12:28:18.000Z - 5 months ago

Immutep sees progress from Phase I study of LAG-3 agonist for autoimmune disease

IMMP

Immutep Limited Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 16, 2026, 8:03 AM EDT - 5 months ago

Immutep Limited Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

IMMP

Immutep downgraded to Hold from Buy at Maxim

2026-03-13T16:52:01.000Z - 5 months ago

Immutep downgraded to Hold from Buy at Maxim

IMMP

Immutep says IDMC recommends discontinuation for TACTI-004 Phase III study

2026-03-13T12:12:46.000Z - 5 months ago

Immutep says IDMC recommends discontinuation for TACTI-004 Phase III study

IMMP

Immutep downgraded to Neutral from Outperform at Baird

2026-03-13T09:35:41.000Z - 5 months ago

Immutep downgraded to Neutral from Outperform at Baird

IMMP

Immutep downgraded to Market Perform from Outperform at Citizens

2026-03-13T08:45:13.000Z - 5 months ago

Immutep downgraded to Market Perform from Outperform at Citizens

IMMP

Immutep Quarterly report: H1 2026

Feb 24, 2026, 6:00 PM EST - 5 months ago

Immutep Quarterly report: H1 2026

Immutep initiated with an Outperform at Citizens

2026-02-17T09:55:08.000Z - 6 months ago

Immutep initiated with an Outperform at Citizens

IMMP

Immutep achieves 50% enrollment in global TACTI-004 Phase III trial

2026-02-06T13:06:35.000Z - 6 months ago

Immutep achieves 50% enrollment in global TACTI-004 Phase III trial

IMMP

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

Feb 6, 2026, 8:00 AM EST - 6 months ago

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

IMMP

Immutep reports Q2 cash receipts from customers A$4,000

2026-01-29T13:21:20.000Z - 6 months ago

Immutep reports Q2 cash receipts from customers A$4,000

IMMP

Immutep Quarterly Activities Report Q2 FY26

Jan 29, 2026, 8:00 AM EST - 6 months ago

Immutep Quarterly Activities Report Q2 FY26

IMMP

Immutep Earnings release: Q2 2026

Jan 28, 2026, 6:00 PM EST - 6 months ago

Immutep Earnings release: Q2 2026

Immutep announces update on IMP761 from Phase I study

2025-12-22T13:15:55.000Z - 8 months ago

Immutep announces update on IMP761 from Phase I study

IMMP

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

Dec 22, 2025, 8:00 AM EST - 8 months ago

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

IMMP

Immutep announces progress in global TACTI-004 Phase III, enrollment continues

2025-12-16T13:15:40.000Z - 8 months ago

Immutep announces progress in global TACTI-004 Phase III, enrollment continues

IMMP MRK

India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug

Dec 8, 2025, 2:34 AM EST - 8 months ago

India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug

IMMP

Immutep Transcript: AGM 2025

Nov 26, 2025, 7:30 PM EST - 9 months ago

Immutep Transcript: AGM 2025

Immutep Slides: FY 2025

Nov 26, 2025, 7:30 PM EST - 9 months ago

Immutep Slides: FY 2025

Immutep Transcript: Bell Potter Healthcare Conference 2025

Nov 19, 2025, 5:00 PM EST - 9 months ago

Immutep Transcript: Bell Potter Healthcare Conference 2025

Immutep Earnings release: Q1 2026

Oct 28, 2025, 6:00 PM EDT - 10 months ago

Immutep Earnings release: Q1 2026

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Oct 20, 2025, 8:01 AM EDT - 10 months ago

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

IMMP

Immutep Annual report: H2 2025

Oct 9, 2025, 10:00 AM EDT - 10 months ago

Immutep Annual report: H2 2025

Immutep Annual report: H2 2025

Oct 9, 2025, 10:00 AM EDT - 10 months ago

Immutep Annual report: H2 2025

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Sep 8, 2025, 8:00 AM EDT - 1 year ago

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

IMMP

Immutep Quarterly Activities Report Q4 FY25

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q4 FY25

IMMP

Immutep Earnings release: Q4 2025

Jul 29, 2025, 6:00 PM EDT - 1 year ago

Immutep Earnings release: Q4 2025

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Jul 29, 2025, 8:00 AM EDT - 1 year ago

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

IMMP

Immutep Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Immutep Transcript: Jefferies Global Healthcare Conference 2025

Immutep Slides: Corporate Presentation

Jun 1, 2025, 6:00 PM EDT - 1 year ago

Immutep Slides: Corporate Presentation

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 27, 2025, 8:00 AM EDT - 1 year ago

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

IMMP

Immutep Earnings release: Q3 2025

Apr 28, 2025, 6:00 PM EDT - 1 year ago

Immutep Earnings release: Q3 2025

Immutep to Participate in Upcoming Investor Conferences

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Immutep to Participate in Upcoming Investor Conferences

IMMP

Immutep Quarterly report: H1 2025

Feb 25, 2025, 6:00 PM EST - 1 year ago

Immutep Quarterly report: H1 2025

Immutep Quarterly Activities Report Q2 FY25

Jan 31, 2025, 8:00 AM EST - 1 year ago

Immutep Quarterly Activities Report Q2 FY25

IMMP

Immutep Earnings release: Q2 2025

Jan 30, 2025, 6:00 PM EST - 1 year ago

Immutep Earnings release: Q2 2025

Immutep Transcript: Baird's Biotech Discovery Series

Dec 19, 2024, 10:15 AM EST - 1 year ago

Immutep Transcript: Baird's Biotech Discovery Series

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Dec 17, 2024, 8:00 AM EST - 1 year ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

IMMP

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Dec 12, 2024, 8:15 AM EST - 1 year ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

IMMP

Immutep Transcript: AGM 2024

Nov 21, 2024, 6:30 PM EST - 1 year ago

Immutep Transcript: AGM 2024

Immutep Slides: FY 2024

Nov 21, 2024, 6:30 PM EST - 1 year ago

Immutep Slides: FY 2024

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Nov 14, 2024, 8:15 AM EST - 1 year ago

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

IMMP

Immutep Quarterly Activities Report Q1 FY25

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q1 FY25

IMMP

Immutep Annual report: H2 2024

Oct 22, 2024, 3:30 AM EDT - 1 year ago

Immutep Annual report: H2 2024

Immutep Annual report: H2 2024

Oct 22, 2024, 3:30 AM EDT - 1 year ago

Immutep Annual report: H2 2024

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

IMMP

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Sep 16, 2024, 8:00 AM EDT - 2 years ago

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

IMMP

Immutep Slides: Corporate Presentation

Aug 21, 2024, 2:00 AM EDT - 2 years ago

Immutep Slides: Corporate Presentation

Immutep Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 14, 2024, 8:30 AM EDT - 2 years ago

Immutep Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Immutep Quarterly Activities Report Q4 FY24

Jul 31, 2024, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q4 FY24

IMMP

Immutep Slides: Study Update Presentation

Jul 11, 2024, 7:00 PM EDT - 2 years ago

Immutep Slides: Study Update Presentation

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Jul 11, 2024, 6:40 PM EDT - 2 years ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

IMMP

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Jul 3, 2024, 8:00 AM EDT - 2 years ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

IMMP

Immutep Slides: Study Result Presentation

Jun 26, 2024, 7:00 PM EDT - 2 years ago

Immutep Slides: Study Result Presentation

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Jun 25, 2024, 8:00 AM EDT - 2 years ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

IMMP

Immutep successfully completes institutional placement and institutional component of entitlement offer

Jun 5, 2024, 6:00 AM EDT - 2 years ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

IMMP

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Jun 2, 2024, 8:38 PM EDT - 2 years ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

IMMP

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

May 15, 2024, 8:00 AM EDT - 2 years ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

IMMP

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

May 2, 2024, 8:00 AM EDT - 2 years ago

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

IMMP

Immutep Quarterly Activities Report Q3 FY24

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q3 FY24

IMMP

Immutep Earnings release: Q3 2024

Apr 28, 2024, 8:00 PM EDT - 2 years ago

Immutep Earnings release: Q3 2024

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

IMMP

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

IMMP

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

IMMP

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Mar 5, 2024, 8:00 AM EST - 2 years ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

IMMP

Immutep Quarterly Activities Report Q2 FY24

Jan 30, 2024, 8:00 AM EST - 2 years ago

Immutep Quarterly Activities Report Q2 FY24

IMMP

Immutep Earnings release: Q2 2024

Jan 30, 2024, 2:30 AM EST - 2 years ago

Immutep Earnings release: Q2 2024

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Jan 4, 2024, 8:00 AM EST - 2 years ago

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

IMMP

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Dec 21, 2023, 8:00 AM EST - 2 years ago

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

IMMP

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Dec 7, 2023, 8:00 AM EST - 2 years ago

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

IMMP

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Nov 22, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

IMMP

TheUsualSuspect007
TheUsualSuspect007 Aug. 10 at 10:56 AM
$IMMP
0 · Reply
theinvestaar
theinvestaar Aug. 10 at 3:04 AM
$IMMP
0 · Reply
ye81
ye81 Aug. 7 at 2:16 PM
$IMMP ⏳🚀🚀
1 · Reply
theinvestaar
theinvestaar Aug. 7 at 1:58 AM
$IMMP Come on Marc!??????
1 · Reply
FROSTCAT
FROSTCAT Aug. 6 at 11:53 AM
$IMMP Old projections don't matter the current setup and data are what count.
0 · Reply
rispi
rispi Aug. 6 at 9:28 AM
$IMMP Just a reminder to all the small ang pumpers around this ticker, they used to talk about 30 usd SP. And they do not even stop talking about finance!!!
0 · Reply
k3vl4r
k3vl4r Aug. 5 at 8:45 PM
$IMMP just hit 100% bullish probability on the 1h-1wk horizon, K3vl4r’s model is all in. One of their top AI reads, but I’ll let the chart speak. #stocks #trading
0 · Reply
FROSTCAT
FROSTCAT Aug. 5 at 2:00 PM
$IMMP let's go
0 · Reply
rispi
rispi Aug. 5 at 9:36 AM
$IMMP let's go fishing
0 · Reply
theinvestaar
theinvestaar Aug. 4 at 8:12 PM
$IMMP News tonight????
2 · Reply
theinvestaar
theinvestaar Aug. 4 at 8:04 PM
$IMMP Hmmmmmn
0 · Reply
FROSTCAT
FROSTCAT Aug. 4 at 4:05 PM
$IMMP The price is holding like it's frozen classic stability before a breakout
0 · Reply
rispi
rispi Aug. 3 at 9:31 AM
$IMMP ohhh boy, deep red even on a flat Aussie day.
1 · Reply
FROSTCAT
FROSTCAT Aug. 2 at 6:02 PM
$IMMP Latest updates look like early rerating signals - bullish tone is justified.
0 · Reply
ShibWillow
ShibWillow Aug. 2 at 5:58 PM
$IMMP
0 · Reply
revuelto
revuelto Jul. 31 at 8:25 PM
$IMMP you should probably read something more than once before dismissing it as garbage…first impressions can be misleading…Immutep has far more to offer and we all know why its cap is where it is today...the moment there’s real clarity in efti, expect a very sharp rerating.
1 · Reply
FORTH3M0N3Y
FORTH3M0N3Y Jul. 31 at 5:32 PM
$IMMP what are the chances of this garbage doing a reverse split and a secondary offering 🤣😂😂
3 · Reply
FROSTCAT
FROSTCAT Jul. 31 at 5:52 AM
$IMMP IMMP has more cash than the market priced in. Quiet now, but this setup often breaks upward.
1 · Reply
joe77w
joe77w Jul. 31 at 5:06 AM
$IMMP It seems a lot of cash, higher than projected.
0 · Reply
FROSTCAT
FROSTCAT Jul. 30 at 8:13 AM
$IMMP https://www.immutep.com/immutep-quarterly-activities-report-q4-fy26/
0 · Reply
theinvestaar
theinvestaar Jul. 30 at 1:15 AM
$IMMP We need updates. 😡🤙🤙🤙
1 · Reply
theinvestaar
theinvestaar Jul. 28 at 12:22 AM
$IMMP Can someone honestly answer this? if it is true, that placebo performed much better than EFTI in some situations and there was a mixup of drug reporting meaning patients really got EFTI and not placebo. What can be done about this? How could they rectify it?
1 · Reply